Internal Medicine, Hematology & Oncology · Robbinsville, NJ
NPI
1881631398
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1 Washington Blvd Ste 9
Robbinsville, NJ, 08691
Phone (732) 314-0540
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
68,351 services
Medicare patients, 2024
607
Average age 76
Drug cost, 2024
$5.0M
1,142 prescriptions
Company payments, 2025
$221
From 11 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Maqsood Amjad was code J1439 (injection, ferric carboxymaltose, 1 mg), 27,000 times for 30 patients. In total Maqsood Amjad billed 68,351 services in 113 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-05-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 27,000 | 30 | $0.85 | $23K |
| 99232 Hospital E&M - Subsequent | Facility | 711 | 206 | $71.87 | $51K |
| 99214 Office E&M - Established | Office | 634 | 261 | $108.62 | $69K |
| 36415 Venipuncture Blood Collection | Office | 524 | 226 | $8.63 | $4,524 |
| 85025 Blood Count | Office | 500 | 208 | $7.55 | $3,775 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 392 | 13 | $0.09 | $35.59 |
| 85027 Blood Count | Office | 219 | 99 | $6.34 | $1,388 |
| 96372 Injection Administration | Office | 189 | 71 | $13.04 | $2,464 |
| 96413 Chemotherapy Administration | Office | 152 | 37 | $120.84 | $18K |
| 96367 Intravenous Infusion, Hydration | Office | 114 | 27 | $26.23 | $2,991 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 106 | 51 | $14.62 | $1,550 |
| 96365 Intravenous Infusion, Hydration | Office | 87 | 56 | $58.76 | $5,112 |
| 99223 Hospital E&M - Initial | Facility | 63 | 62 | $157.75 | $9,939 |
| 99213 Office E&M - Established | Office | 57 | 43 | $72.85 | $4,152 |
| 99215 Office E&M - Established | Office | 51 | 39 | $153.78 | $7,843 |
By year: 2022 $625K for 40,233 services; 2023 $1.1M for 63,252 services; 2024 $1.3M for 68,351 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 524 | 226 | $8.63 | $4,524 |
| 85025 Blood Count | 500 | 208 | $7.55 | $3,775 |
| 85027 Blood Count | 219 | 99 | $6.34 | $1,388 |
Medicare prescription drug claims, 2024
In 2024, the drug Maqsood Amjad prescribed most often to Medicare patients was Eliquis (Apixaban), with 89 prescriptions and refills. In total Maqsood Amjad wrote 1,142 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 89 | 185 | 26 | $106K |
| Aranesp Darbepoetin Alfa In Polysorbat | 85 | 85 | 14 | $180K |
| Anastrozole Generic | 82 | 183 | 22 | $1,995 |
| Procrit Epoetin Alfa | 56 | 56 | Under 11 | $105K |
| Calquence Acalabrutinib Maleate | 53 | 53 | Under 11 | $790K |
| Hydroxyurea Generic | 45 | 89 | Under 11 | $711 |
| Acyclovir Generic | 37 | 41 | Under 11 | $424 |
| Revlimid Lenalidomide | 33 | 33 | Under 11 | $665K |
| Warfarin Sodium Generic | 33 | 51 | Under 11 | $291 |
| Jakafi Ruxolitinib Phosphate | 23 | 23 | Under 11 | $404K |
| Gabapentin Generic | 22 | 30 | Under 11 | $117 |
| Dexamethasone Generic | 20 | 28 | Under 11 | $264 |
| Palonosetron Hcl Generic | 18 | 18 | Under 11 | $1,558 |
| Nplate Romiplostim | 18 | 18 | Under 11 | $280K |
| Folic Acid Generic | 17 | 23 | Under 11 | $140 |
Brand drugs: 610 claims; generic drugs: 532 claims; opioid claims: 19.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Maqsood Amjad $221 ($221 in general payments such as food, travel and fees) from 11 companies. The largest payer was Abbvie Inc. with $37.02.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 2 | $37.02 |
| Aveo Pharmaceuticals, Inc. | 1 | $26.04 |
| Myriad Genetic Laboratories, Inc. MYGN | 1 | $18.91 |
| Incyte Corporation INCY | 1 | $18.75 |
| Exelixis Inc. EXEL | 1 | $18.6 |
| Genentech USA, Inc. ROG.SW | 1 | $18.41 |
| PharmaEssentia USA Corporation 6446.TW | 1 | $18.27 |
| Array Biopharma Inc PFE | 1 | $18.23 |
| Telix Pharmaceuticals TLX | 1 | $17.91 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $15.74 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.